PSMB9 and nasopharyngeal carcinoma: A phase II clinical trial carried out in 19 advanced stage NPC patients assessed the safety and the antitumor effects of DC transduced with a recombinant Ad5 vector and coding for a truncated LMP1 and a full-length LMP2 protein.